Estimating demand for potential disease-modifying therapies for Alzheimer's disease in the UK.
Axel Anders Stefan LaurellAshwin V VenkataramanTatjana SchmidtMarcella MontagneseChristopher MuellerRobert J StewartJonathan LewisClare MundellJeremy D IsaacsMani S KrishnanRobert BarberTimothy RittmanBenjamin R UnderwoodPublished in: The British journal of psychiatry : the journal of mental science (2024)
Monoclonal antibody treatments for Alzheimer's disease are likely to present a significant challenge for healthcare services to deliver in terms of the neuroimaging and treatment delivery. The data provided here allows health services to understand the potential demand and plan accordingly.